Medicine and Dentistry
Crohn's Disease
82%
Inflammatory Bowel Disease
78%
Surgery
56%
Patient with Crohn's Disease
42%
Recurrent Disease
37%
Patient with Inflammatory Bowel Disease
31%
Neoplasm
28%
Systematic Review
26%
Meta-Analysis
24%
Diseases
23%
Infection
22%
Primary Sclerosing Cholangitis
20%
Cohort Analysis
19%
Adalimumab
15%
Colitis
15%
Thrombocyte Rich Plasma
15%
Hazard Ratio
15%
Tumor Necrosis Factor
14%
Fistula
13%
Organoid
13%
Immunomodulating Agent
12%
Vedolizumab
12%
Cholangiocarcinoma
12%
Coronavirus Infection
11%
Odds Ratio
11%
Diagnosis
11%
Bowel Resection
11%
COVID-19
11%
Antiviral Therapy
11%
Randomized Controlled Trial
10%
Coronavirus
10%
Coronavirinae
10%
Monkeypox
10%
Magnetic Resonance Imaging
9%
Faecal Calprotectin
9%
Next Generation Sequencing
9%
Dysplasia
9%
Immunosuppressant
9%
Quality of Life
9%
Adverse Event
8%
Tofacitinib
8%
Virus Replication
8%
Population
7%
Cardiovascular Disease
7%
Adipose Tissue
7%
Gene Mutation
7%
Disease Activity
7%
Prospective Study
7%
Clinical Management
7%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
100%
Inflammatory Bowel Disease
45%
Recurrent Disease
35%
Remission
33%
Tumor Necrosis Factor
26%
Inflammation
22%
Adalimumab
21%
Ustekinumab
21%
Diseases
19%
Tofacitinib
19%
Infection
17%
Vedolizumab
17%
Immunosuppressive Agent
13%
Immunomodulating Agent
12%
Coronavirus Infection
12%
Ulcerative Colitis
12%
Calgranulin
12%
Cohort Study
11%
Antivirus Agent
10%
Adverse Event
10%
Colitis
8%
Combination Therapy
8%
Molnupiravir
7%
Randomized Controlled Trial
7%
Mercaptopurine
7%
Biological Product
7%
Prospective Study
7%
Antiviral Activity
6%
C Reactive Protein
5%
Tumor Necrosis
5%
Tacrolimus
5%
Tumor Necrosis Factor Inhibitor
5%
Necrosis
5%
Proctitis
5%
Aminosalicylic Acid
5%
Indometacin
5%
Fistula
5%
Beclometasone
5%
Primary Sclerosing Cholangitis
5%
Neoplasm
5%
Hepatitis E
5%
Monotherapy
5%
Anemia
5%
Iron Deficiency
5%
Suppository
5%
Nirmatrelvir
5%
Clinical Feature
5%
Monkeypox
5%
Ileum
5%
Comorbidity
5%
Immunology and Microbiology
Inflammatory Bowel Disease
42%
Crohn's Disease
42%
Adalimumab
21%
Coronavirinae
16%
Vedolizumab
13%
COVID-19
12%
Organoid
12%
Tumor Necrosis Factor
10%
Primary Sclerosing Cholangitis
10%
Coronavirus
9%
Viral Replication
8%
Inflammation Response
7%
Quality Adjusted Life Year
7%
Colon
6%
Macrophage
6%
Viral Disease
6%
Airway
6%
Drug Therapy
6%
Breakthrough Infection
5%
Indoleamine 2,3-dioxygenase
5%
Seroconversion
5%
Disease Burden
5%
Hepatitis E
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
NLRP3 Inflammasome
5%
Cell Proliferation
5%
Immunomodulating Drugs
5%
Immunodeficiency
5%
Stem Cell
5%
Cell Lineage
5%
Monkeypox
5%
Stroma
5%
Platelet
5%
Myeloid
5%
Interleukin 17
5%
Primary Immunodeficiency
5%
